Table 2 VIB4920 demonstrates an acceptable safety profile in patients with RA.

VIB4920 demonstrates an acceptable safety profile in patients with RA..

Subjects withPlacebo
(n = 15)
VIB4920
(75 mg; n = 8)
VIB4920
(500 mg; n = 10)
VIB4920
(1000 mg; n = 12)
VIB4920
(1500 mg; n = 12)
VIB4920
(total; n = 42)
≥1 event13 (86.7%)3 (37.5%)7 (70.0%)6 (50.0%)10 (83.3%)26 (61.9%)
≥1 related event5 (33.3%)1 (12.5%)5(50.0%)3 (25.0%)6 (50.0%)15 (35.7%)
≥1 event of ≥grade 3 severity*001 (10.0%)1 (8.3%)1 (8.3%)3 (7.1%)
Death (grade 5 severity)000000
≥1 serious event00001 (8.3%)1 (2.4%)
≥1 serious and/or ≥grade 3
severity event
001 (10.0%)1 (8.3%)1(8.3%)3 (7.1%)
≥1 related serious event000000
≥1 event leading to discontinuation of
investigational product
01 (12.5%)001 (8.3%)2 (4.8%)

*Subject 20022150007 on 500-mg dose reported three grade 3 adverse events concomitantly (10 to 24 February 2017); PTs: sinusitis, sinus polyp, and nasal turbinate hypertrophy; subject 20024460007 on 1000-mg dose reported a grade 3 event of worsening diabetes mellitus.

†Subject 20022150009 reported serious adverse event of preferred term encephalitis.